Providers/Grant Support
Provided by The Obesity Society and DKBmed, LLC.
This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Credits Available
- Physicians — maximum of 0.75 AMA PRA Category 1 Credits™
All other healthcare professionals completing this course will be issued a statement of participation
Target Audience
This educational program is designed for Endocrinologists, Hepatologists, Primary Care Physicians (MDs and DOs), and Advanced Practice Providers (e.g., Nurse Practitioners (NPs) and Physician Associates (PAs) working in specialty or primary care clinics. A secondary audience also includes Pharmacists.
Program Overview
This on-demand webcast series will change the way you diagnose and manage Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD). MASLD is the most common cause of chronic liver disease worldwide and growing in prevalence, but as many as half of patients may be undiagnosed. MASLD is hidden in plain sight.
In this session recorded at ObesityWeek® 2025, you’ll meet a patient and walk through their diagnosis and treatment. You’ll discover:
- The surprising prevalence of MASLD
- Accurate testing methods and which patients to screen
- Therapeutic targets that have the biggest impact
- Emerging treatments that could change the landscape
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Identify and articulate the pathophysiologic mechanisms that underlie the development and progression of MASLD.
- Evaluate and apply evidence-based strategies to improve detection of MASLD, MASH, and fibrosis.
- Analyze the natural history and clinical consequences of MASLD to differentiate disease stages and describe outcomes.
- Critically appraise and synthesize safety and efficacy findings from recent clinical trials of dual GLP-1/glucagon receptor agonists for MASH treatment.
Faculty
Jaime P. Almandoz, MD, MBA, FTOS, DABOM
Medical Director, Weight Loss Wellness Program
UT Southwestern Medical Center
Dallas, TX
Lee M. Kaplan, MD, PhD, FTOS
Professor and Chief,
Section of Obesity Medicine
Geisel School of Medicine at Dartmouth
Wellesley, MA
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Obesity Society and DKBmed. The Obesity Society is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
The Obesity Society designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim credit commensurate with the extent of their participation in the activity.
Disclosures of Conflict of Interest
Jaime Almandoz, MD, MBA, DABOM, FTOS
- Advisor (includes corporate or scientific advisory boards): Lilly, Novo Nordisk
- Advisor: Amgen, AbbVie, Kailera, Metsera, Boehringer Ingelheim, Rivus, Rhythm
Lee Kaplan, MD, PhD, FTOS
- Consultant: Altimmune, Amgen, AstraZeneca, Boehringer Ingelheim, Dil Figaro, Genentech, The Last Food Fight, Lilly, Johnson & Johnson, Kallyope, Metsera, Oxford Medical Perspectum, Products, Neurogastrx, Novo Nordisk, Pfizer, Structure, Skye
Instructions for Participation and Credit
If you wish to receive acknowledgment for completing this activity, please complete the evaluation.
Course Viewing Requirements
Supported Browsers:
Desktop: Newest and last prior version of Google Chrome, Firefox, Safari, and Microsoft Edge
Mobile devices: Newest and last prior version of Safari and Google Chrome
Supported Phones & Tablets:
All devices
Disclosure of Unlabeled Use
Faculty have indicated that they will be referencing unlabeled/unapproved uses of tirzepatide, retatrutide, survodutide, mazdutide, efruxifermin and pegozafermin.
Disclaimer
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Contact Information
For CME questions please contact: [email protected]